Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis

This is a prospective, single center, safety and feasibility trial to evaluate the transplantation of the left atrium and pulmonary veins in patients with pulmonary vein stenosis. Consented patients will be listed for transplantation. Once a suitable donor has been identified, the left atrium, pulmonary veins and complete lung block will be harvested from the donor and transported to Boston Children's Hospital as is the procedure for routine lung transplantation patients. The left atrium and pulmonary veins will be transplanted into the recipient. The recipient will receive the normal immunosuppression protocol used for heart transplantation.

This pilot study will include 5 patients.

Study Overview

• Status: Suspended
• Conditions: Pulmonary Vein Stenosis
• Intervention / Treatment: Procedure: LA transplant

Detailed Description

Techniques for harvest of the posterior left atrium and pulmonary veins from a suitable organ donor have been well established as this is currently accomplished during every harvest of lungs for lung transplantation. The difference in this therapy is that the lung parenchyma will not be utilized. However, the harvest from the donor will be exactly the same with the full lung block typically harvested for lung transplant removed and transported back to the site of implantation. The exact extent of pulmonary vein utilization from the lung block will be determined at the time of implantation based on the exact anatomy and location of the pulmonary vein disease of the recipient.

As this represents a new transplantation approach, this program has been discussed with the United Network for Organ Sharing (UNOS) and the New England Organ Bank (NEOB). UNOS identified this as a new area of transplantation related to but separate from heart or lung transplantations. Eventually if this progresses to a national phase, it will require creation of a new patient waiting list and all the policies that accompany a new area of transplantation. Although there is enthusiasm at UNOS for this approach, they recommended that it be pursued as a regional research program as an initial step. The NEOB also has voiced support for this program in a meeting with them including their medical director. They are interested in supporting this program as a Region 1 research program and will perform a full evaluation for approval once local IRB approval has been granted. The Children's team will work closely with NEOB to create a list of potential patients and identify suitable donors.

Utilizing standardized harvesting techniques will minimize any changes to the current harvest approach and definition of tissue allocation during the harvest procedure. As the lung parenchyma is unnecessary, it is expected that suitable donors for left atrial transplant would come from two sources:

• The first source is brain dead donors in whom the lungs are not allocated for transplantation based on rejection of the lungs for quality or no matching donors.
• The second source is donors after cardiac death (DCD) which are utilized in the adult population for kidney, liver and lung transplantation. DCD organs are not currently utilized pediatric lung transplantation. However, as the viability of these tissues, including the entire lung block is well established, these represent a potential donor pool for left atrial transplant patients.

Certainly experience with preservation of the kidney grafts for hours or days with integrated perfusion systems has demonstrated the successful implantation of vascularized tissues appropriately preserved can be extended beyond the traditional four hour window targeted for lung transplantation. Kidney transplants are commonly done within 24 hours without evidence of impact on the vascular patency these grafts. In addition, only vascular tissue is being transplanted that has no effect on gas exchange or contractility. Accordingly it is expected that the goal implantation time for left atrial transplants after harvest will not need to be within the four to six hour window used for lung transplant but can be safely extended to 24 hours. This window extends the donor pool for left atrial transplants to the entire country.

Excision of recipient left atrium and stenotic pulmonary veins and implantation of left atrial graft The set up for the operation will be identical to all major cardiopulmonary bypass cardiac cases. The surgical approach for the recipient will likely be a clamshell incision that crosses the sternum in the fourth interspace. This is the same incision used for lung transplant. The patient will be cannulated for cardiopulmonary bypass in the distal aorta, SVC and low in the IVC. Cardiopulmonary bypass will be initiated and the patient will be cooled to 18°C. Prior to arresting the heart, the donor left atrium and pulmonary veins will be inspected in the lung block. The pulmonary veins from the donor will be mobilized and prepared for resection from the lung block.

The cross clamp will be applied and the heart arrested. The pulmonary veins of the recipient will be mobilized and transected beyond the level stenoses. The left atrium and pulmonary vein graft then be brought to the field and positioned in the orthotopic position.

The anastomosis of the pulmonary veins will be completed with a generous diameter of the anastomotic area to minimize any risk of late anastomotic narrowing even in the smallest of pulmonary vein segments. The donor left atrium will be anastomosed to the posterior left atrial cuff of the heart. Only the affected pulmonary veins with stenosis will be transplanted. This may be one or up to all 4 main pulmonary veins. If an individual pulmonary vein or side of pulmonary veins are unaffected, they will not have any manipulation or intervention on them. A formal atrial fenestration will be created. Post-bypass evaluation with transesophageal echocardiogram will assess pulmonary vein velocities and flow. The chest will be closed and patient transferred intubated to the ICU.

In the initial clinical experience with these transplants, a traditional immunosuppression protocol for heart transplants will be followed. Over time new protocols will be developed and tested which focused on minimizing the long-term immunosuppression regimens.

• Study Type: Interventional
• Enrollment (Anticipated): 5
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • Boston Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 17 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Pulmonary vein stenosis involving at least one but up to all of the main pulmonary veins following initial treatment, including but not limited to balloon dilation, stenting, surgical repair or chemotherapy
• Focal pulmonary stenosis limited to the main pulmonary veins or their first or second order branches.

Exclusion Criteria:

• Diffuse pulmonary vein stenosis involving long segments of one or more pulmonary veins including diffuse stenosis into the second order pulmonary vein branches or beyond
• Significant underlying lung disease
• Irreversible pulmonary artery hypertension exceeding indexed 10 Woods units (WU)
• Irreversible multisystem organ failure; or additive effects of multiple systems affected making transplant survival unlikely
• Progressive systemic disease with early mortality (genetic/metabolic, idiopathic, syndromic)
• Morbid obesity (BMI>30)
• Diabetes mellitus with evidence of end-organ damage
• Severe chromosomal, neurologic or syndromic abnormalities
• Active infection
• HIV or chronic hepatitis B or C infection
• Severe left ventricular dysfunction
• Malignancy within 5 years prior to transplant
• Severe renal or liver failure
• Inadequate social support for post-transplant management
• Recent history of illicit drug, tobacco or alcohol abuse despite trials/assistance to stop behavior
• Episode of acute rejection within the previous 6 months
• Post-transplant lymphoproliferative disease that has been within two years
• Evidence of large stroke with high risk for hemorrhagic conversion

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LA transplantation; The left atrium and pulmonary veins will be transplanted into the recipient	Procedure: LA transplant; The proposed study treatment will include three central components: Harvest of the left atrium and pulmonary veins from a suitable donor; Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis; Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Short term survival	Mortality rate at 30 days following transplantation.	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary vein patency	The study team will assess for the flow through the transplanted pulmonary veins.	30 days
Long term survival	Mortality rate at 6 months following transplantation.	6 months
Long term pulmonary vein patency and gradient	The study team will assess for the flow through the transplanted pulmonary veins and any increased gradient through the transplanted pulmonary veins (gradient through transplanted veins that has been deemed greater than mild).	6 months
Right ventricular pressure	The study team will assess for any increase in right ventricular pressure and/or concerns for developing pulmonary hypertension.	6 months

Collaborators and Investigators

• Sponsor: Boston Children's Hospital
• Investigators: Principal Investigator: David Hoganson, MD, Boston Children's Hospital

Publications and helpful links

General Publications

• Sadr IM, Tan PE, Kieran MW, Jenkins KJ. Mechanism of pulmonary vein stenosis in infants with normally connected veins. Am J Cardiol. 2000 Sep 1;86(5):577-9, A10. doi: 10.1016/s0002-9149(00)01022-5.
• Devaney EJ, Chang AC, Ohye RG, Bove EL. Management of congenital and acquired pulmonary vein stenosis. Ann Thorac Surg. 2006 Mar;81(3):992-5; discussion 995-6. doi: 10.1016/j.athoracsur.2005.08.020.
• Yun TJ, Coles JG, Konstantinov IE, Al-Radi OO, Wald RM, Guerra V, de Oliveira NC, Van Arsdell GS, Williams WG, Smallhorn J, Caldarone CA. Conventional and sutureless techniques for management of the pulmonary veins: Evolution of indications from postrepair pulmonary vein stenosis to primary pulmonary vein anomalies. J Thorac Cardiovasc Surg. 2005 Jan;129(1):167-74. doi: 10.1016/j.jtcvs.2004.08.043.
• Bharat A, Epstein DJ, Grady M, Faro A, Michelson P, Sweet SC, Huddleston CB. Lung transplant is a viable treatment option for patients with congenital and acquired pulmonary vein stenosis. J Heart Lung Transplant. 2013 Jun;32(6):621-5. doi: 10.1016/j.healun.2013.03.002.

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2022
• Primary Completion (Anticipated): September 1, 2025
• Study Completion (Anticipated): September 1, 2025

Study Registration Dates

• First Submitted: February 22, 2018
• First Submitted That Met QC Criteria: February 28, 2018
• First Posted (Actual): March 7, 2018

Study Record Updates

• Last Update Posted (Actual): November 23, 2021
• Last Update Submitted That Met QC Criteria: November 15, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Pathological Conditions, Anatomical; Constriction, Pathologic; Stenosis, Pulmonary Vein
• Other Study ID Numbers: IRB-P00023581

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No